Hanna Panfilova, Oleh Samborskyi, Natalia Bogdan, Oksana Tsurikovа, Liusine Simonian
Hanna Panfilova1*, Oleh Samborskyi2, Natalia Bogdan3, Oksana Tsurikovа4, Liusine Simonian1
1Faculty of Pharmacy, Department of Organization and Economics of Pharmacy,
National University of Pharmacy, Ukraine.
2Faculty of Pharmacy, Department of Organization and Economy of Pharmacy and Drug Technology,
Ivano-Frankivsk National Medical University, Ukraine.
3Faculty of Pharmacy, Department of Pharmacy of Higher State Educational Establishment of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine.
4Faculty of Pharmacy, Department of Quality Management, National University of Pharmacy, Ukraine.
Volume - 14,
Issue - 5,
Year - 2021
This article presents the analysis results of Ukrainian pharmaceutical market segment of stomach ulcer treatment drugs. It was determined that, judging by the quantitative indexes, Ukrainian market of anti-ulcer medication is an actively developing structure that maintains the stability of its development qualitative characteristics nonetheless. For example, during two years (01 June 2016 – 01 June 2018) the quantities of medicinal products and companies that represent these products in Ukraine have both grown: from 396 to 448 names (13.13%) and from 90 companies (25 of them Ukrainian) to 98 (28, correspondingly). On the background of quantity growth of Ukrainian-made drugs from 84 (2016) to 92 (2018), the specified market segment has shown significant dependency on import. For example, the proportion (%) of foreign production drugs has grown from 78.79% (2016) to 79.46% (2018). KRKA is an uncontested leader by the quantity of marketed medicinal products (2016 – 28 products, 2018 – 32 products). The products of Takeda Pharmaceutical Company Limited are presented in the second place (22 and 23 products, corresponding to the years under study). The products of Dr. Reddy's Laboratories take the third place (20 and 21 products, corresponding to the years under study). The said pharmaceutical market segment has kept its monopolistic pattern of distribution as judged by the manufacturing companies whose products are presented in Ukraine, and by international non-proprietary names of products and their pharmacotherapeutic groups. For example, just 8 foreign manufacturing companies were responsible for 40.17% (2016) and 31.92% (2018) of imported assortment of anti-ulcer drugs, and 7 domestic companies were responsible for 64.29% (2016) and 61.54% (2018) of domestic assortment of these drugs. In 2016 75.76% and in 2018 – 71.65% of the whole assortment of anti-ulcer drugs were presented by the drugs from the following groups: A02B-Drugs for peptic ulcer and gastro-oesophageal reflux disease (Gord), A02BC Proton pump inhibitors (55.30% and 50.22%, corresponding to the years under study). Five drugs (A02BC02-Pantoprazole, A02BC01-Omeprazole, A02BC05-Esomeprazole, A02BC03-Lansoprazole, A02BD Combinations for eradication of Helicobacter pylori) presented more than a half of marketed assortment of anti-ulcer products (2016 – 56.57%, and 2018 – 55.14%). Tableted dosage forms (2016 – 58.33%, and 2018 – 55.80%) and drugs of synthetic origin (2016 – 76.26%, and 2018 – 78.13%) have kept their leading positions on the market. Authors have discovered that during 2015-2018 the average retail prices of anti-ulcer drugs have shown the trend of systematic growth. The highest growth of average retail prices was observed for A02BX13-Alginic acid ( avg.=1.37), and the lowest ? for A02BC06-Dexlansoprazole ( avg.=1.04). The given above characteristics of the market segment that was studied allow us to state the need to develop and establish the national program of import substitution for the assortment of anti-ulcer drugs in Ukraine.
Cite this article:
Hanna Panfilova, Oleh Samborskyi, Natalia Bogdan, Oksana Tsurikovа, Liusine Simonian. Study of Development problems dynamics of Ukrainian market of stomach ulcer treatment drugs. Research Journal of Pharmacy and Technology. 2021; 14(5):2502-0. doi: 10.52711/0974-360X.2021.00441
Hanna Panfilova, Oleh Samborskyi, Natalia Bogdan, Oksana Tsurikovа, Liusine Simonian. Study of Development problems dynamics of Ukrainian market of stomach ulcer treatment drugs. Research Journal of Pharmacy and Technology. 2021; 14(5):2502-0. doi: 10.52711/0974-360X.2021.00441 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-5-25
1. Brown K, Lundborg P, Levinson J, Yang H. Incidence of peptic ulcer bleeding in the US pediatric population. J Pediatr Gastroenterol Nutr. 54(6); 2012: 733-36.
2. Sung JJ., Kuipers EJ., El-Serag H.B. Systematic review: The global incidence and prevalence of peptic ulcer disease. Aliment. Pharmacol. Ther. 29; 2009: 938-46.
3. Friedman GD, Siegelaub AB, Seltzer CC. Cigarettes, alcohol, coffee and peptic ulcer. N Engl J Med 290(9); 1974: 469-73.
4. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut. 48(3); 2001: 287-9.
5. Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking. J Clin Gastroenterol. 24(1); 1997: 2-17.
6. Benjamin Scally, Jonathan R. Emberson, Enti Spata et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet. Gastroenterol & Hepatology. 3(4); 2018: 231-41.
7. Go MF. Natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 16(1); 2002: 3-15.
8. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther.17; 2003: 1333-43.
9. Gustafson J, D. Welling. “No Acid, No Ulcer”‒100 Years Later: A Review of the History of Peptic Ulcer Disease. Journal of the American College of Surgeons. 210(1); 2009: 110-16.
10. Serdyuk NM, Vamalyuk IP, Stasyshyn OS. Internal Medicine. Therapy. Kiev, Medicine. 2011.
11. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 8; 2011: 79-8.
12. Jayaram V, Aiyappa C, Jallihal U and Shivamurthy MC: Prescription pattern of drugs used in the treatment of peptic ulcer disease in the department of gastroenterology in a tertiary care hospital. Int J Pharm Sci Res. 5(6); 2014: 2418-22.
13. Sonnenberg A Review article: historic changes of Helicobacter pylori-associated diseases. Aliment Pharmacol Ther. 38; 2013: 329-42
14. Del Valle J Peptic ulcer disease and related disorders. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 19nd ed. NY: McGraw Hill Education. 2015.
15. Julia Fashner, Alfred C. Gitu. Diagnosis and Treatment of Peptic Ulcer Disease and H. pylori Infection Am Fam Physician. 91(4); 2015: 236-42.
16. Stephen W. Behrman. Management of Complicated Peptic Ulcer Disease Arch Surg. 140(2); 2005: 201-08.
17. Emma Sverdén, M.D. Complicated peptic ulcer disease: prevention and treatment. Sweden, Stockholm: Karolinska Institutet. 2017. Available from: URL: https://openarchive.ki.se/xmlui/bitstream/handle/10616/45516/Thesis_Emma_Sverdén.pdf?sequence=1&isAllowed=y.
18. Sostres C, Lanas A. Epidemiology and demographics of upper gastrointestinal bleeding: prevalence, incidence, and mortality. Gastrointest Endosc Clin N Am. 21(4); 2011: 567-81.
19. Lanas A Chan FKL. Peptic ulcer disease. Lancet. 390; 2017: 613-24
20. Pilotto A, Franceschi M, Maggi S et al. Optimal management of peptic ulcer disease in the elderly. Drugs & Aging. 27(1); 2010: 545-58.
21. Kizlova N, Ocheredko O. Evaluation of the effectiveness of the rehabilitation program in patients with newly diagnosed episodes of gastric ulcer and duodenal ulcer Science Rise: Medical Science. 6(2); 2016: 46-50.
22. Kizlova N, Ocheredko O. Evaluation of recurrenth spitalization probability in patients with duodenal and gastric ulcer dependent upon rehabilitation input EUREKA: Health Sciences.3; 2016: 36-40.
23. Kalmykova YuS. Complex physical rehabilitation for peptic ulcer and duodenal ulcer. Kharkiv: KDAFK; 2012.
24. Tikhonov OІ, Bogdan NS, Shpichak OS. Marketings of the military market of anti-eradication preparations and accessibility for the population of Ukraine. Management, Economics and Quality Assurance in Pharmacy. 4; 2016: 78-89.
25. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP: Meta-analysis: Esomeprazole or Rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 36(5); 2012: 414-25.
26. John Dell Valle: Peptic ulcer disease and related disorders. Harrison's Principles of Internal Medicine. 19nd ed. NY: McGraw-Hill. 2014.
27. The order of the Ministry of Health of Ukraine № 613 vіd 03.09.2014 p. "About the hardened and in voprovennya medical-medical documents for standardization medically help with peptic viral shunka and two intestines". Available from: URL: http://www.moz.gov.ua/ua/portal/ dn_20140903_0613.html.
28. Janet Peacock, Philip Peacock Oxford Handbook of Medical Statistics. Oxford: Oxford University Press; 2011.
29. Ji-Qian Fang, editor. Handbook of Medical Statistics. China: Sun Yat-Sen University. 2017.
30. Leontiadis GI, Sreedharan A, Dorward S et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess. 11; 2007: 1-164.
31. Fashner J, Gitu AC. Common gastrointestinal symptoms: risks of long-term proton pump inhibitor therapy. FP Essent. 413; 2013: 29-39.
32. National Bank of Ukraine. Officianal website. Information materials. Operative state of the foreign exchange market. Archive. Available from: URL: https://bank.gov.ua/control/uk/publish/article?art_id=9628619&cat_id=9628618. National strategy for reforming the health care system in Ukraine for the period 2015-2025. Ministry of Health of Ukraine. International Renaissance Foundation. 2015. Available from: URL: http://healthsag.org.ua/wp-content/uploads/2014/11/Proekt-Strategiyi-reformi_OZ.pdf.
33. Medical reform by the Ministry of Health: What is waiting for doctors and patients in 2018? Available from: URL: http://www.apteka.ua/article/440234.
34. Mandache RC, Boboia A. Research on the pharmaceutical market in Europe and Romania. Rev. Int. Comp. Manag.16(4); 2015: 528-39.
35. Global Medicines Use in 2020 Outlook and Implications Available from: URL: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in-2020.pdf?la=uk-ua&hash=968B71C0B0769A179F3A56E331C62754EEF74752.
36. Global Anti-ulcer Drug Market Insights, Forecast to Available from: URL: https://qyresearch.us/report/global-anti-ulcer-drug-market-2018/379859/.